Lymphatic Filariasis Elimination Program – Articles By Carter Center Experts

Dec. 10, 2011
Lymphatic Filariasis in Western Ethiopia With Special Emphasis on Prevalence of Wuchereria Bancrofti Antigenaemia In and Around Onchocerciasis Endemic Areas
This article was published online on Dec. 10, 2011 in Transactions of the Royal Society of Tropical Medicine and Hygiene. Reprinted with permission.
Authors: Welelta Shiferaw,Tadesse Kebede,Patricia M. Graves,Lemu Golasa,Teshome Gebre,Aryc W. Mosher,Abiot Tadesse,Heven Sime,Tariku Lambiyo,K.N. Panicker,Frank O. Richards,Asrat Hailu
Lymphatic filariasis is known to be endemic in Gambella Region, western Ethiopia, but the full extent of its endemicity in other regions is unknown. A national mapping program for Ethiopia was initiated in 2008. This report summarizes initial data on the prevalence of Wuchereria bancrofti antigenaemia based on surveys carried out in a sampled population of 11 685 individuals living in 125 villages (112 districts) of western Ethiopia.

Oct. 11, 2011
Epidemiological and Entomological Evaluations after Six Years or More of Mass Drug Administration for Lymphatic Filariasis Elimination in Nigeria (PDF)
This article was published in the Oct. 11, 2011, issue of PLoS Journal of Neglected Tropical Diseases and is reprinted with permission.
Richards FO, Eigege A, Miri ES, Kal A, Umaru J, et al. 2011. PLoS Negl Trop Dis 5(10): e1346. doi:10.1371/journal.pntd.0001346. The current strategy for interrupting transmission of lymphatic filariasis (LF) is annual mass drug administration (MDA), at good coverage, for 6 or more years. We describe our programmatic experience delivering the MDA combination of ivermectin and albendazole in Plateau and Nasarawa states in central Nigeria, where LF is caused by anopheline transmitted Wuchereria bancrofti.

March 30, 2010
A Project for Haiti: The Eradication of Two Diseases
This letter to the editor of the New York Times by Carter Center Vice President for Health Programs Dr. Donald R. Hopkins was published March 30, 2010, in response to the March 28, 2010 editorial "Making Haiti Whole."
Two projects that the donors conference on Haiti should consider this week are the binational plan that Haiti and the Dominican Republic announced last October to eliminate malaria by 2020, and the plan that Haiti announced simultaneously to eliminate lymphatic filariasis (elephantiasis) by 2020 (the Dominican Republic expects to eliminate lymphatic filariasis this year).

Jan. 1, 2008
Collecting Baseline Information for National Morbidity Alleviation Programs: Different Methods to Estimate Lymphatic Filariasis Morbidity Prevalence (PDF)
Am. J. Trop. Med. Hyg., 78(1), 2008, pp. 153–158, Copyright © 2008 by The American Society of Tropical Medicine and Hygiene. Authors: Els Mathieu,* Josef Amann, Abel Eigege, Frank Richards, and Yao Sodahlon. Abstract: The lymphatic filariasis elimination program aims not only to stop transmission, but also to alleviate morbidity. Although geographically limited morbidity projects exist, few have been implemented nationally. For advocacy and planning, the program coordinators need prevalence estimates that are currently rarely available. This article compares several approaches to estimate morbidity prevalence: (1) data routinely collected during mapping or sentinel site activities; (2) data collected during drug coverage surveys; and (3) alternative surveys. Data were collected in Plateau and Nasarawa States in Nigeria and in 6 districts in Togo.

Jan. 1, 2002
Lymphatic Filariasis Elimination and Schistosomiasis Control in Combination with Onchocerciasis Control in Nigeria
Authors: Hopkins D.R., Eigege A., Miri E.S., Gontor, I., Ogah, G., Umaru, J., Gwomkudu, C.C., Mathai, W., Jinadu, M.Y., Amadiegwu, S., Oyenekan, O.K., Korve, K., Richards, F.O. Published in American Journal of Tropical Medicine and Hygiene. 2002; 67(3):266-72. Abstract: This paper describes a pilot initiative to incorporate lymphatic filariasis (LF) elimination and urinary schistosomiasis (SH) control into a mature onchocerciasis control program bsed on community-directed ivermectin treatment in central Nigeria. In the same districts having onchocerciasis we found LF (as determined by blood antigen testing in adult males) in 90% of 149 villages with a mean prevalence of 22.4% (range 0-67%). Similarly, SH, as a mean prevalence in school age children of 24.4% (range 0-87%). Health education and treatment interventions for SH resulted in 52,480 cumulative praziquantel treatments, and 159,555 combined onchocerciasis and LF treatments (with ivermectin and albendazole) as of the end of 2000. Treatments for onchocerciasis and LF were separated by at least 1 week from treatments for SH. There was no negative impact on the coverage of the onchocerciasis program by the addition of LF and SH activities.